fbpx
  • Facebook
  • Instagram
  • Linkedin
  • Twitter
  • Gplus
  • Mail
My Onco Path
  • HOME
  • PATIENTS
  • PROVIDERS
  • NEWS
  • FAQs
  • BOARD OF DIRECTORS
  • ABOUT
  • CONTACT
  • Menu
Genetic Testing Options, News, Personalized Cancer Treatments

Vitrakvi approved for NTRK+ cancers | MyOncoPath

0 Comments
/
March 6, 2019
FDA approves Vitrakvi in all tumor types with NTRK gene variants Progress…
https://myoncopath.com/wp-content/uploads/2019/03/Screen-Shot-2019-03-06-at-11.52.12-AM.png 295 611 hwetzel https://myoncopath.com/wp-content/uploads/2017/07/myoncopath_test_3.svg hwetzel2019-03-06 16:55:032019-05-16 19:22:45Vitrakvi approved for NTRK+ cancers | MyOncoPath

Archive

  • November 2019
  • April 2019
  • March 2019
  • January 2019
  • April 2018
  • February 2018
  • January 2018
  • December 2017
  • October 2017
  • September 2017

Categories

  • Genetic Testing Options
  • News
  • Personalized Cancer Treatments
  • Symposium Conference
  • Telemedicine

Facebook

MyOncoPath
Call: 1.888.335.8006 or 1.925.266.5777.
Email: contact@myoncopath.com

Our Disclaimer

Partnerships


Contact Us

About

© My Onco Path - Enfold WordPress Theme by Kriesi
Download Our Whitepaper

Scroll to top